aminolevulinic acid hydrochloride
Phase 2Small molecule
aminolevulinic acid hydrochloride is one of 56 small molecule programs targeting Pediatric Brain Tumor. It is currently in Phase 2.
2
Indications
11
Total Trials
2
Active Trials
55
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
59 competitors in Glioblastoma Multiforme
#DrugCompanyPhaseTrials
1Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Avastin
RochePhase 3
Istodax
TevaApproved
Lynparza
AstraZenecaApproved
Niacor
AbbVieApproved
Bayer Aspirin
BayerApproved
Keppra
UCBApproved
Cialis
Eli LillyApproved
Talzenna
PfizerApproved
Stivarga
BayerApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Skin Cancer2 trials
Head and Neck Tumors1 trial
Photodynamic Therapy in Treating Patients With Premalignant or Early Stage Head and Neck Tumors
Completed·—·Phase 1·NCT00978081·35 enrolled
Efficacy and Safety1 trial
5 more indications
Chronic Lymphocytic Leukemia1 trial
Cheilitis1 trial
Photodynamic Therapy (PDT) With Levulan and Blue Light for the Treatment of Actinic Cheilitis
Completed·—·Phase 4·NCT02409732·24 enrolled
Pediatric Brain Tumor1 trial
Glioblastoma Multiforme1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- MMayo Clinic